BRIEF published on 11/20/2024 at 17:05, 20 hours 50 minutes ago Director's Share Purchase at Molten Ventures London Stock Exchange Ordinary Shares Share Purchase Molten Ventures Ben Wilkinson
PRESS RELEASE published on 11/20/2024 at 17:00, 20 hours 55 minutes ago Director/PDMR Shareholding Molten Ventures Plc board member Ben Wilkinson, Chief Executive Officer, purchased 13,007 ordinary shares at £3.094 each on 20-Nov-2024, London Stock Exchange London Stock Exchange Molten Ventures Plc Share Purchase Financial Transaction Ben Wilkinson
BRIEF published on 11/20/2024 at 08:05, 1 day 5 hours ago Molten Ventures Reports Interim Results for Six Months Ending September 2024 Portfolio Management Investment Strategy Venture Capital Interim Results Réalisations
PRESS RELEASE published on 11/20/2024 at 08:00, 1 day 5 hours ago Molten Ventures Plc: Interim Results Molten Ventures Plc announces its interim results for the six-month period ending on 30 September 2024, reporting stable financial highlights and strategic investments. CEO outlines positive realisations and capital deployment Investment Strategy Financial Highlights Venture Capital Molten Ventures Interim Results
BRIEF published on 11/11/2024 at 08:05, 10 days 5 hours ago Molten Ventures Announces Interim Results Presentation Venture Capital Molten Ventures Webcast Presentation Interim Results Tech Investment
PRESS RELEASE published on 11/11/2024 at 08:00, 10 days 5 hours ago Interim Results FY25 Analyst and Investor Presentations Molten Ventures plc announces live webcast for FY25 interim results with analyst and investor presentations on 20 Nov 2024. Details at moltenventures.com Molten Ventures Plc Venture Capital Investor Presentations FY25 Interim Results Analyst Presentations
BRIEF published on 10/31/2024 at 19:04, 20 days 18 hours ago BlackRock Increases Stake in Molten Ventures Plc Acquisition Voting Rights BlackRock Molten Ventures Securities Lending
PRESS RELEASE published on 10/31/2024 at 18:59, 20 days 18 hours ago Molten Ventures Plc: HOL-Holding(s) in Company* BlackRock, Inc. notifies an acquisition of voting rights in Molten Ventures Plc on Oct 30, 2024 Acquisition Voting Rights Molten Ventures Plc Notification BlackRock, Inc.
BRIEF published on 10/30/2024 at 08:06, 22 days 5 hours ago Molten Ventures Reports Stable Half-Year Performance Financial Results CEO Transition Portfolio Performance Molten Ventures Réalisations
BRIEF published on 10/30/2024 at 08:05, 22 days 5 hours ago Leadership Transition at Molten Ventures Strategic Development Leadership Transition Venture Capital Molten Ventures CEO Changes
Published on 11/21/2024 at 13:30, 25 minutes ago AirIQ Announces September 30, 2024 Quarterly Results Company Reports Double-Digit Growth in Recurring Revenue
Published on 11/21/2024 at 13:30, 25 minutes ago Datametrex Secures Additional P.O. Approx $250K for IT Services
Published on 11/21/2024 at 13:00, 55 minutes ago Aclara Secures Funding from Corfo's Innovation High-Tech Program for Artificial Intelligence Project
Published on 11/21/2024 at 13:00, 55 minutes ago Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
Published on 11/21/2024 at 13:00, 55 minutes ago Toggle3D.ai Rebrands as FOTOgpt.ai to Usher in a New Age of AI-Powered Photography
Published on 11/21/2024 at 12:35, 1 hour 20 minutes ago audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 1 hour 40 minutes ago Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 06:58, 6 hours 57 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 18 hours 35 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 20 hours 10 minutes ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 20 hours 10 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 6 hours ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo
